Lanadelumab for prevention of attacks of non-histaminergic normal C1 inhibitor angioedema: results from the randomized, double-blind CASPIAN Study and CASPIAN open-label extension.

Conclusion Although the primary efficacy endpoint was not met in CASPIAN, the efficacy of lanadelumab in the studied population of patients with non-histaminergic nC1INH angioedema showed a positive trend in reducing angioedema attack rates.

also in 11,005 other papers

Patients in the lanadelumab group had a marked and sustained reduction in pKal activity; furthermore, an apparent trend of reduction in cHMWK activity was observed with lanadelumab versus placebo.

also in 709 other papers